Lidocaine/Heparin

利多卡因/肝素

Report date: 2026/02/13 10:40:15

Base Information

Drug NameLidocaine/Heparin
Drug Alias NameU-101URG-101Hep-Lido-AVNX001VNX-001
ClassificationSmall molecules
Mechanisms of ActionAntithrombin-III activatorsSodium channel alpha subunit modulators
TargetsSodium channel alpha subunitAntithrombin-III
Therapy Area/IndicationsPelvic PainCystitis, InterstitialUrinary Bladder Diseases +[5
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwan
CombinationsYes Heparin sodiumLidocaine
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
China Registration ClassN/A

Develop Information

Inactive CompaniesUrigen
Active IndicationsCystitis, InterstitialUrinary Tract InfectionsCommunicable Diseases
Inactive IndicationsPelvic PainUrinary Bladder Diseases

Other Information

ATC CodeN/A
Related LinksN/A